TNGX · Tango Therapeutics, Inc. · Metrics
$21.93
-0.78 (-3.43%)
At close · Nov 20
Return incl. dividend (before tax)
Market Cap
$3.85B
Shares
169.46M
Volume · Nov 20
932.36K
Avg daily vol (3M)
3.41M
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
TNGX metrics
70 of 125 screener metrics currently available.
Market overview
2 metricsShare price
$22.71
Market cap
$3.85B
Price action
23 metricsPrice change (1W)
-8.6%
Price change (30D)
-15.8%
Price change (3M)
-3.4%
Price change (6M)
+5.0%
Price change (YTD)
+156.3%
Price change (1Y)
+174.1%
Trailing year
Price change (5Y)
+89.7%
52-week high
$32.90
52-week low
$8.29
Change from 52-week high
-31.0%
Change from 52-week low
+174.1%
Annualized volatility
101.5%
Annualized volatility (3M)
78.6%
Implied volatility (30D)
82.9%
IV rank (1Y)
17.7
IV percentile (1Y)
25.0
Beta
1.6
RSI (14D)
47.6
Price vs SMA 50
-3.3%
Price vs SMA 200
-1.7%
Avg volume (3M)
3.41M
Relative volume
0.5
Average dollar volume
$80.23M
Company
3 metricsSector
Healthcare
Industry
Biotechnology
Shares outstanding
169.46M
Valuation
12 metricsP / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
—
P / book
3.9
reciprocal yield 25.5%
FCF yield
—
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-5.4%
Historical valuation
8 metricsP / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—
Dividends & buybacks
7 metricsDividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—
Earnings calendar
2 metricsNext earnings
—
Last earnings
—
Profitability
9 metricsGross margin
—
Operating margin
—
Trailing 12 months
Net margin
—
Gross profit (TTM)
—
Operating profit (TTM)
−$228.53M
Net income (TTM)
−$208.00M
Trailing 12 months
Diluted EPS (TTM)
$-1.37
FCF margin
—
Effective tax rate
—
Growth
11 metricsRevenue growth YoY
-100.0%
Year over year
Net income growth YoY
-530.6%
Revenue (TTM)
$0
Trailing 12 months
EPS growth YoY
-400.0%
Shares change YoY
+47.7%
Year over year · more shares
Revenue CAGR (3Y)
+35.9%
Revenue CAGR (5Y)
+52.1%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—
Quality
14 metricsReturn on equity
-21.2%
Return on assets
-20.1%
Debt / equity
—
Current ratio
39.4
EBITDA (TTM)
—
Free cash flow (TTM)
—
Quick ratio
39.4
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
$977.50M
Latest balance sheet
Cash & equivalents
$86.83M
Total assets
$1.03B
Total debt
—
Cash flow & spend
7 metricsOperating cash flow (TTM)
−$150.09M
Capital expenditures (TTM)
$277,000
R&D (TTM)
$151.76M
SG&A (TTM)
—
Stock compensation (TTM)
$58.58M
R&D / revenue
—
Stock compensation / revenue
—
Ownership (13F)
9 metrics13F filers
257
13F filer change QoQ
+10
Institutional ownership
126.0%
Conviction holders (share of 13F filers)
7.4%
Crowding (high-turnover and private-fund holders)
—
Private-fund adviser ownership
—
Active holders' share change QoQ
-0.3%
Holder tenure
9.1
Price vs estimated holder cost
+56.4%
Ownership (registered funds)
1 metricsIndex-fund ownership
12.5%
Short interest
3 metricsShort interest
28.5%
Latest settlement · 9.7 days to cover
Days to cover
9.7d
Short-squeeze score
77 / 100
Insider activity
2 metricsNet insider buying (90D)
−$1.94M
Insider-sentiment score
—
Risk flags
1 metricsGoing concern
—
Key facts
CIK
1819133
CUSIP
87583X109
13F (30d)
267 filings
250 filers
Visit website
Investor relations